| CIN (n = 14) | No CIN (n = 172) | P |
Male/Female | 12/2 | 124/48 | 0.3587 |
Age (Years) | 70.8 ± 6.2 | 72.6 ± 8.2 | 0.4837 |
HT (%) | 5 (36%) | 70 (41%) | 0.7147 |
DM (%) | 5 (36%) | 60 (35%) | 0.8190 |
SCr (mg/dl) | 0.80 ± 0.22 | 0.84 ± 0.22 | 0.7745 |
eGFR (mL/min/1.73 mm2) | 76.2 ± 23.7 | 68.4 ± 19.0 | 0.5561 |
eGFR < 60 mL/min (%) | 5 (36%) | 68 (40%) | 0.7783 |
Previous TACE sessions | 3.4 ± 3.0 | 2.5 ± 2.6 | 0.3461 |
Multiple HCC (%) | 10 (71%) | 117 (68%) | 0.9718 |
Diameter max HCC (mm) | 37.0 ± 35.8 | 28.4 ± 18.8 | 0.2895 |
Contrast volume (mL) | 154 ± 43 | 147 ± 45 | 0.4671 |
Chemotherapy |
|
| 0.1668 |
Miriplatin | 3 | 75 |
|
Cisplatin | 11 | 78 |
|
Epirubisin | 2 | 19 |
|
Child-Pugh class B or C | 10 (71%) | 70 (41%) | 0.0459* |
Ascites | 2 (14%) | 29 (17%) | 0.5883 |
HBsAg-positive | 3 (21%) | 15 (8.7%) | 0.2817 |
HCVAb-positive | 9 (64%) | 121 (70%) | 0.8629 |
Albumin (g/dl) | 3.0 ± 0.5 | 3.4 ± 0.6 | 0.0175* |
Total bilirubin (mg/dl) | 1.0 ± 0.5 | 0.9 ± 0.5 | 0.1940 |
AST (mg/dl) | 70.8 ± 54.0 | 59.7 ± 40.4 | 0.6739 |
ALT (mg/dl) | 50.7 ± 45.2 | 47.3 ± 42.0 | 0.7391 |
Prothrombin time (INR) | 1.16 ± 0.31 | 1.22 ± 0.81 | 0.2794 |
Platelet count | 11.7 ± 6.2 | 11.8 ± 5.4 | 0.7725 |
Hemoglobin | 10.6 ± 2.0 | 11.8 ± 2.0 | 0.0351* |
AFP (ng/mL) | 1105 ± 3132 | 842 ± 2074 | 0.6029 |
PIVKA-II (IU/mL) | 249 ± 455 | 1854 ± 6688 | 0.1969 |